With its cutting-edge siRNA platform technology, RADS, Argo Biopharma is able to provide Best-In-Class candidates for a range of indications.
Argo's extensive pipeline encompasses a wide range of therapeutic areas, including cardiovascular, metabolic disorders, hematological, CNS, hepatitis, and complement mediated diseases. We recognize that collaborating with other organizations can expedite the advancement of our novel medications towards clinical trials and eventual commercialization. To expand our wide pipelines, we are open to out-licensing, asset acquisitions, and strategic partnerships.

If you are interested, please contact us: BD@argobiopharma.com.